BioNexus Gene Lab Corp.
BGLC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $9,827 | $5,516 | $4,240 | $5,031 |
| - Cash | $1,153 | $814 | $3,595 | $4,377 |
| + Debt | $184 | $197 | $200 | $211 |
| Enterprise Value | $8,858 | $4,899 | $845 | $864 |
| Revenue | $2,544 | $2,260 | $2,137 | $2,524 |
| % Growth | 12.5% | 5.8% | -15.3% | – |
| Gross Profit | $378 | $368 | $343 | $309 |
| % Margin | 14.8% | 16.3% | 16.1% | 12.3% |
| EBITDA | -$666 | -$570 | -$547 | -$373 |
| % Margin | -26.2% | -25.2% | -25.6% | -14.8% |
| Net Income | -$709 | -$616 | -$623 | -$348 |
| % Margin | -27.9% | -27.3% | -29.2% | -13.8% |
| EPS Diluted | -0.39 | -0.34 | -0.35 | -0.19 |
| % Growth | -14.7% | 2.9% | -84.2% | – |
| Operating Cash Flow | -$1,233 | -$738 | -$824 | -$54 |
| Capital Expenditures | -$5 | -$21 | -$9 | -$4 |
| Free Cash Flow | -$1,239 | -$759 | -$833 | -$58 |